Nicotine lozenge and patch combined help to quit smoking faster
Digg
del.icio.us
Facebook
Reddit
Google
Stumble Upon
Fark
Newsvine
YahooBuzz
Bebo
Twitter
Independent Minds
enlarge
No matter how many times you try, quitting smoking is never easy. But new research shows that the nicotine patch combined with a nicotine lozenge is the most effective method of kicking the habit.
In a comparison of five different products aimed at quitting smoking, which included using the nicotine lozenge alone, the nicotine patch alone, or Zyban, an antidepressant also marketed as Wellbutrin, alone or in combination with the lozenge, two combined methods proved better than one.
"If you combine these different types of nicotine replacement you're going to get the best bang for your buck," said Megan E. Pipera, assistant professor at the Center for Tobacco Research and Intervention at the University of Wisconsin who led the research.
When compared with a placebo, all of the smoking cessation treatments showed some effectiveness, but the patch and the lozenge together had the highest likelihood of continued success, i.e., total abstinence from smoking after six months.
The tests also showed that people taking the patch-lozenge combination were more likely to have given up cigarettes after only a week and have attained a full day without smoking more rapidly.
The nicotine patch has been on the market for over 20 years and is currently the most widely used pharmacotherapy used for quitting smoking.
Because the lozenge mimics the nicotine boost associated with smoking, the researchers said that used alone, it is unlikely to be effective because it could encourage cravings.
The report appears in the November issue of Archives of General Psychiatry.
View all comments that have been posted about this article.
Offensive or abusive comments will be removed and your IP logged and may be used to prevent further submission. In submitting a comment to the site, you agree to be bound by the Independent Minds Terms of Service.
- Print Article
- Email Article
-
Click here for copyright permissions
Copyright 2009 Independent News and Media Limited
Comments
Financial Disclosure: The authors report the following potential conflicts of interest for the last 5 years: Dr Smith has received research support from Elan Corporation. Dr Baker has served as an investigator on research projects sponsored by pharmaceutical companies, including Sanofi-Synthelabo, Pfizer Inc, and Nabi Biopharmaceuticals. Dr Jorenby has received research support from the National Institute on Drug Abuse, the National Cancer Institute, Pfizer Inc, Sanofi-Synthelabo, and Nabi Biopharmaceuticals. He has received support for educational activities from the National Institute on Drug Abuse and the Veterans Administration and consulting fees from Nabi Biopharmaceuticals. Dr Fiore has received honoraria from Pfizer. He has served as an investigator on research studies at the University of Wisconsin that were funded by Pfizer, Sanofi-Synthelabo, GlaxoSmithKlein, and Nabi Biopharmaceuticals. In 1998, the University of Wisconsin appointed Dr Fiore to a named chair funded by an unrestricted gift to University of Wisconsin from Glaxo Wellcome. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.